Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other

APLP1 and APLP2, members of the APP family of proteins, behave similarly to APP in that they associate with NMDA receptors and enhance NMDA receptor surface expression

(2015) Sarah L. Cousins et al.   JOURNAL OF NEUROCHEMISTRY

Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function

(2015) Rachel M. DeVay et al.   PLoS One

Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9

(2014) Evan A. Stein et al.   Annual Review of Medicine

Sorting an LDL receptor with bound PCSK9 to intracellular degradation

(2014) Trond P. Leren   ATHEROSCLEROSIS

The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion

(2014) Camilla Gustafsen et al.   Cell Metabolism

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

Amyloid Precursor-Like Protein 2 Increases the Endocytosis, Instability, and Turnover of the H2-Kd MHC Class I Molecule

(2014) A. Tuli et al.   JOURNAL OF IMMUNOLOGY

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies

(2013) Nabil G. Seidah   CURRENT PHARMACEUTICAL DESIGN

Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2)

(2013) Rachel M. DeVay et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Intracellular Domain of Sortilin Interacts with Amyloid Precursor Protein and Regulates Its Lysosomal and Lipid Raft Trafficking

(2013) Miao Yang et al.   PLoS One

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

(2013) Maryssa Canuel et al.   PLoS One

SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion

(2013) Xiao-Wei Chen et al.   eLife

Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia

(2012) Marianne Abifadel et al.   ATHEROSCLEROSIS

Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9

(2012) Javier Chaparro-Riggers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway

(2012) Yascara Grisel Luna Saavedra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Loss- and Gain-of-function PCSK9 Variants

(2012) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR

(2012) Yan Wang et al.   JOURNAL OF LIPID RESEARCH

Comparative analysis of virus–host interactomes with a mammalian high-throughput protein complementation assay based on Gaussia princeps luciferase

(2012) Grégory Neveu et al.   METHODS

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue

(2011) Anna Roubtsova et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

(2011) Paola Lo Surdo et al.   EMBO REPORTS

Benchmarking a luciferase complementation assay for detecting protein complexes

(2011) Patricia Cassonnet et al.   NATURE METHODS

In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9

(2010) Rachid Essalmani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of the Prosegment and pH on the Activity of PCSK9

(2010) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain

(2010) Thea Bismo Strøm et al.   MOLECULAR GENETICS AND METABOLISM

The inactivation of the sortilin gene leads to a partial disruption of prosaposin trafficking to the lysosomes

(2009) Jibin Zeng et al.   EXPERIMENTAL CELL RESEARCH

Mechanism for Amyloid Precursor-like Protein 2 Enhancement of Major Histocompatibility Complex Class I Molecule Degradation

(2009) Amit Tuli et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

(2009) Markey C. McNutt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

(2009) Steve Poirier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

New Insights into the Structural Mechanisms of the COPII Coat

(2009) Christopher Russell et al.   TRAFFIC

Degradation of LDLR protein mediated by ‘gain of function’ PCSK9 mutants in normal and ARH cells

(2008) Tommaso Fasano et al.   ATHEROSCLEROSIS

Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

(2008) Ahmed Zaid et al.   HEPATOLOGY

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA